Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Enzyme Deficiency Improves Clinical Picture in Mouse Model of Gaucher's Disease

By BiotechDaily International staff writers
Posted on 10 Feb 2014
Image: Elevation of RIPK3 in nuclei of neurons (red; arrows) from neuronopathic Gaucher's disease mice (Photo courtesy of Dr. Anthony Futerman, Weizmann Institute of Science).
Image: Elevation of RIPK3 in nuclei of neurons (red; arrows) from neuronopathic Gaucher's disease mice (Photo courtesy of Dr. Anthony Futerman, Weizmann Institute of Science).
Blocking the activity of a specific enzyme reversed the clinical symptoms of Gaucher's disease (GD) in a mouse model of this hereditary lipid storage disease.

GD is a hereditary disease caused by a recessive mutation in a gene located on chromosome 1 that causes a deficiency of the enzyme glucocerebrosidase. This enzyme acts on the fatty acid glucosylceramide, and when the enzyme is defective, glucosylceramide accumulates, particularly in white blood cells, most often macrophages. Glucosylceramide can also collect in the spleen, liver, kidneys, lungs, brain, and bone marrow. Clinical manifestations may include enlarged spleen and liver, liver malfunction, skeletal disorders and bone lesions that may be painful, severe neurological complications, swelling of lymph nodes, distended abdomen, a brownish tint to the skin, anemia, low blood platelets and yellow fatty deposits on the white of the eye.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) examined the role of the enzyme Ripk3 (receptor-interacting serine-threonine-protein kinase 3) in GD. Ripk3, the product of the RIPK3 gene, is predominantly localized to the cytoplasm, and can undergo nucleocytoplasmic shuttling dependent on novel nuclear localization and export signals. It is a component of the tumor necrosis factor (TNF) receptor-I signaling complex, and can induce apoptosis and weakly activate the transcription factor NF-kappaB.

To study the relationship between Ripk3 and GD the investigators used a GD mouse model that included animals with and without active Ripk3. Results published in the January 19, 2014, online edition of the journal Nature Medicine revealed that Ripk3 deficiency substantially improved the clinical course of GD in the mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury. Furthermore, the lifespan of these mice was remarkably increased, from approximately 35 days to more than 170 days.

“If successful, the new target could be used as either a complementary or alternative therapy for Gaucher's disease, and with RIPK3 proving to be a "hot" cellular pathway in various pathologies, these results may also have implications in other neurodegenerative diseases, including related diseases such as Krabbe disease, and potentially other devastating brain diseases,” said senior author Dr. Anthony Futerman, professor of biological chemistry at the Weizmann Institute of Science.

Related Links:

Weizmann Institute of Science
 


Channels

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

“Softer” Mass Spec Techniques Gain Advantage in Biomarker Discovery

Two mass spectrometry (MS) technologies, MALDI and DESI, are increasing in applications as their effectiveness is established, according to Kalorama Information (New York, NY, USA) in its report “Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays,... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.